Effect of long-term oral pretreatment with levosimendan on cardiac arrhythmias during coronary artery occlusion in conscious rats

Heart failure is frequently associated with cardiac arrhythmias. The aim of the present study was to investigate the effect of levosimendan, a new cardiotonic drug for the treatment of congestive heart failure, on experimental ischaemic arrhythmias. Acute coronary artery occlusion was produced in conscious rats 7-10 days after placement of ligature around the left main coronary artery. Acute pretreatment with levosimendan (0.2 or 0.6 mg/kg orally 1 h before coronary artery occlusion) did not influence the incidence, onset and duration of arrhythmias. Long-term pretreatment with levosimendan (0.2 or 0.6 mg/kg orally twice a day for 2 weeks) increased the survival rate (50% and 81% vs. 44% in controls) and the number of animals without any arrhythmia (37% and 31% vs. 5% in controls). The present results demonstrate that chronic oral treatment with levosimendan could be beneficial in congestive heart failure and arrhythmias resulting from regional myocardial ischaemia.